Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 5
2011 7
2012 2
2013 3
2014 6
2015 9
2016 6
2017 8
2018 5
2019 7
2020 13
2021 2
2022 6
2023 13
2024 5
2025 5
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

102 results

Results by year

Filters applied: . Clear all
Page 1
OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF; PREEMPT Chronic Migraine Study Group. Dodick DW, et al. Headache. 2010 Jun;50(6):921-36. doi: 10.1111/j.1526-4610.2010.01678.x. Epub 2010 May 7. Headache. 2010. PMID: 20487038 Clinical Trial.
OBJECTIVE: To assess the efficacy, safety, and tolerability of onabotulinumtoxinA (BOTOX) as headache prophylaxis in adults with chronic migraine. BACKGROUND: Chronic migraine is a prevalent, disabling, and undertreated neurological disorder. .. …
OBJECTIVE: To assess the efficacy, safety, and tolerability of onabotulinumtoxinA (BOTOX) as headache prophylaxis in adults with c …
OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF; PREEMPT 1 Chronic Migraine Study Group. Aurora SK, et al. Cephalalgia. 2010 Jul;30(7):793-803. doi: 10.1177/0333102410364676. Epub 2010 Mar 17. Cephalalgia. 2010. PMID: 20647170 Clinical Trial.
OBJECTIVES: This is the first of a pair of studies designed to assess efficacy, safety and tolerability of onabotulinumtoxinA (BOTOX) as headache prophylaxis in adults with chronic migraine. METHODS: The Phase III REsearch Evaluating Migraine Prophylax …
OBJECTIVES: This is the first of a pair of studies designed to assess efficacy, safety and tolerability of onabotulinumtoxinA (BOTOX) …
OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.
Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF; PREEMPT 2 Chronic Migraine Study Group. Diener HC, et al. Cephalalgia. 2010 Jul;30(7):804-14. doi: 10.1177/0333102410364677. Epub 2010 Mar 17. Cephalalgia. 2010. PMID: 20647171 Clinical Trial.
OBJECTIVES: This is the second of a pair of studies designed to evaluate the efficacy and safety of onabotulinumtoxinA (BOTOX) for prophylaxis of headaches in adults with chronic migraine. METHODS: PREEMPT 2 was a phase 3 study, with a 24-week, double- …
OBJECTIVES: This is the second of a pair of studies designed to evaluate the efficacy and safety of onabotulinumtoxinA (BOTOX) for pr …
An academic debate: OnabotulinumtoxinA for chronic migraine: PREEMPT-derived vs "customized" dosing/injection paradigm.
Green MW, Rothrock JF. Green MW, et al. Toxicon. 2018 Jun 1;147:116-119. doi: 10.1016/j.toxicon.2018.03.011. Epub 2018 Mar 27. Toxicon. 2018. PMID: 29596847 Review.
In 2010 onabotulinumtoxinA (OnabotA) was approved by the United States Food and Drug Administration for the treatment of chronic migraine (CM). Data supporting approval were derived primarily from two parallel placebo-controlled trials, the PREEMPT stu …
In 2010 onabotulinumtoxinA (OnabotA) was approved by the United States Food and Drug Administration for the treatment of chronic …
OnabotulinumtoxinA: Still the Present for Chronic Migraine.
Baraldi C, Lo Castro F, Ornello R, Sacco S, Pani L, Guerzoni S. Baraldi C, et al. Toxins (Basel). 2023 Jan 10;15(1):59. doi: 10.3390/toxins15010059. Toxins (Basel). 2023. PMID: 36668879 Free PMC article. Review.
OnabotulinumtoxinA (BT-A) is one of the few drugs approved for the preventive treatment of chronic migraine (CM). ...Recently, novel findings have led to a better understanding of its pharmacological actions and clinical usefulness in migraine preventi …
OnabotulinumtoxinA (BT-A) is one of the few drugs approved for the preventive treatment of chronic migraine (CM). ...Re …
Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials.
Silberstein SD, Diener HC, Dodick DW, Sommer K, Lipton RB. Silberstein SD, et al. Headache. 2024 Jul-Aug;64(7):838-848. doi: 10.1111/head.14743. Epub 2024 Jun 22. Headache. 2024. PMID: 38982666 Clinical Trial.
OBJECTIVE: To characterize the long-term (56-week) benefits of continuous onabotulinumtoxinA treatment response in individuals with chronic migraine (CM) who achieved reduction to <15 headache days/month with treatment. ...We assessed the long-term impact …
OBJECTIVE: To characterize the long-term (56-week) benefits of continuous onabotulinumtoxinA treatment response in individuals with …
OnabotulinumtoxinA injection in the treatment of chronic migraine.
Wang YF. Wang YF. Prog Brain Res. 2020;255:171-206. doi: 10.1016/bs.pbr.2020.05.013. Epub 2020 Jun 30. Prog Brain Res. 2020. PMID: 33008506 Review.
It was until the Phase III REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) 1 and 2 studies when its efficacy and safety, as well as the indication, i.e., chronic migraine (CM), were ascertained. Even though there were criticisms regarding th …
It was until the Phase III REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) 1 and 2 studies when its efficacy and sa …
Development of onabotulinumtoxinA for chronic migraine.
Whitcup SM, Turkel CC, DeGryse RE, Brin MF. Whitcup SM, et al. Ann N Y Acad Sci. 2014 Nov;1329:67-80. doi: 10.1111/nyas.12488. Epub 2014 Aug 18. Ann N Y Acad Sci. 2014. PMID: 25399521 Free article. Review.
Discovery of the neuromuscular effects of botulinum toxin began in the early 19th century and has continued to evolve. Currently, onabotulinumtoxinA is approved by the U.S. Food and Drug Administration for two cosmetic and eight medical indications, including chronic …
Discovery of the neuromuscular effects of botulinum toxin began in the early 19th century and has continued to evolve. Currently, onabotu …
OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine.
Frampton JE, Silberstein S. Frampton JE, et al. Drugs. 2018 Apr;78(5):589-600. doi: 10.1007/s40265-018-0894-6. Drugs. 2018. PMID: 29532439 Free PMC article. Review.
An intramuscular formulation of onabotulinumtoxinA (onabotA; Botox( )) is currently the only therapy specifically approved for the prevention of headaches in adults with chronic migraine (CM) in the EU and North America. ...More recently, the efficacy and tol …
An intramuscular formulation of onabotulinumtoxinA (onabotA; Botox( )) is currently the only therapy specifically approved for the pr …
Injection technique of the upper face with onabotulinumtoxinA in chronic migraine.
Boczarska-Jedynak M, Blumenfeld AM. Boczarska-Jedynak M, et al. Headache. 2023 Jul-Aug;63(7):849-860. doi: 10.1111/head.14588. Epub 2023 Jun 27. Headache. 2023. PMID: 37366143 Review.
OnabotulinumtoxinA is an effective medication for the prevention of chronic migraine. The PREEMPT injection paradigm has been validated in randomized clinical trials and real-world settings. ...Often patients who have been injected with onabotulinum …
OnabotulinumtoxinA is an effective medication for the prevention of chronic migraine. The PREEMPT injection para …
102 results